BR112022014694A2 - Composições biofarmacêuticas e métodos relacionados - Google Patents

Composições biofarmacêuticas e métodos relacionados

Info

Publication number
BR112022014694A2
BR112022014694A2 BR112022014694A BR112022014694A BR112022014694A2 BR 112022014694 A2 BR112022014694 A2 BR 112022014694A2 BR 112022014694 A BR112022014694 A BR 112022014694A BR 112022014694 A BR112022014694 A BR 112022014694A BR 112022014694 A2 BR112022014694 A2 BR 112022014694A2
Authority
BR
Brazil
Prior art keywords
related methods
biopharmaceutical compositions
compositions
biopharmaceutical
antagonism
Prior art date
Application number
BR112022014694A
Other languages
English (en)
Inventor
Neelon Kelly
Zhang Mingxuan
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of BR112022014694A2 publication Critical patent/BR112022014694A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A presente invenção refere-se a composições compreendendo anticorpos anti-PD-1 e métodos relacionados para tratar câncer e outros distúrbios responsivos ao antagonismo de PD-1.
BR112022014694A 2019-12-18 2020-12-10 Composições biofarmacêuticas e métodos relacionados BR112022014694A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US201962950595P 2019-12-19 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
BR112022014694A2 true BR112022014694A2 (pt) 2022-09-06

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014694A BR112022014694A2 (pt) 2019-12-18 2020-12-10 Composições biofarmacêuticas e métodos relacionados

Country Status (11)

Country Link
US (1) US20230059341A1 (pt)
EP (1) EP4077388A1 (pt)
JP (1) JP2023507981A (pt)
KR (1) KR20220129548A (pt)
CN (1) CN115298218A (pt)
AU (1) AU2020407007A1 (pt)
BR (1) BR112022014694A2 (pt)
CA (1) CA3164600A1 (pt)
IL (1) IL293753A (pt)
MX (1) MX2022007464A (pt)
WO (1) WO2021126657A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
AU2014259719B2 (en) 2013-05-02 2019-10-03 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
TWI750133B (zh) * 2015-08-24 2021-12-21 美商葛蘭素史密斯克萊有限責任公司 生藥組成物
EP3534950A4 (en) * 2016-11-01 2020-05-06 AnaptysBio, Inc. ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1)
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
JP2023507981A (ja) 2023-02-28
IL293753A (en) 2022-08-01
KR20220129548A (ko) 2022-09-23
MX2022007464A (es) 2022-06-27
WO2021126657A1 (en) 2021-06-24
CN115298218A (zh) 2022-11-04
EP4077388A1 (en) 2022-10-26
US20230059341A1 (en) 2023-02-23
CA3164600A1 (en) 2021-06-24
AU2020407007A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2018016344A (es) Miembros de union lag-3.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
NZ728688A (en) Anti-pd-1 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
BR112018012801A2 (pt) combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MA40074A (fr) Composés liant ras multivalents
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
BR112016014731A2 (pt) Anticorpos anti-baff
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
EP3768727A4 (en) NEW BIS SPECIFIC PD-1 / LAG-3 ANTIBODY MOLECULES
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
EP3823978A4 (en) FCRN ANTIBODY COMPOSITIONS